// App-Quantinova.ai

: Impact of risankizumab on improving health-related quality of life, work productivity, and reducing fatigue among patients with active psoriatic arthritis: A pooled analysis of two Phase 3 clinical trials

Researchers

Presenter

  • Lars Erik Kristensen

Principal Investigators

  • Ahmed M. Soliman

  • Kim Papp

  • Lisa Barcomb

  • Ann Eldred

  • Zailong Wang

  • Douglas White

  • Frank Behrens

Medical Centers

  • The Parker Institute, Department of Rheumatology, Copenhagen University Hospital at Frederiksberg, Copenhagen, Denmark

  • AbbVie, Inc., North Chicago, IL

  • K. Papp Clinical Research and Probity Medical Research, Waterloo, ON, Canada, Waterloo, ON, Canada

  • Rheumatology Department, Waikato Hospital, Hamilton, New Zealand, and Waikato Clinical School, University of Auckland, Auckland, New Zealand

  • Rheumatology, Fraunhofer Institute Translational Medicine and Pharmacology ITMP & Cluster of Excellence CIMD, Goethe University, Frankfurt, Germany

Locations

  • United Kingdom

  • Canada

  • United States

  • Denmark

  • New Zealand

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • Risankizumab

  • Tilisolol

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved